Post-Polycythemia Vera Myelofibrosis - Pipeline Insight, 2024

This “Post-Polycythemia Vera Myelofibrosis - Pipeline Insight, 2024” report provides comprehensive insights about 17+ companies and 17+ pipeline drugs in Post-Polycythemia Vera Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Post-Polycythemia Vera Myelofibrosis: Understanding

Post-Polycythemia Vera Myelofibrosis: Overview

Polycythemia Vera that changes into MF is referred to as post-polycythemia vera myelofibrosis (PPV-MF). MF is also a rare, chronic blood cancer. People with MF have a defect in their bone marrow that results in an abnormal production of blood cells, causing scar tissue to form.

Post-Polycythemia Vera Myelofibrosis are the most common type of intracranial tumor. In the United States, an estimated 98,000 to 170,000 cases occur each year. The incidence of Post-Polycythemia Vera Myelofibrosis is increasingly likely as a result of several factors. Patients with a systemic metastatic disease have a longer survival with new systemic therapies (including immunotherapy) that have recently seen more widespread use. Furthermore, the growing use of sensitive magnetic resonance imaging (MRI) techniques has contributed to the better detection of small asymptomatic Post-Polycythemia Vera Myelofibrosis.

Pathophysiology
The bone marrow of patients with polycythemia vera (PV) contains normal stem cells and contains abnormal clonal stem cells that suppress normal stem cell growth and maturation. The cause of panmyelosis is unregulated neoplastic proliferation. JAK2 kinase mutation likely leads to the signaling derangements resulting in PV. A valine to phenylalanine substitution at position 617 of the JAK2 gene, or JAK2V617F, leads to constitutively active cytokine receptors. This mutation is observed in over 90% of patients with PV and 50% to 60% of primary myelofibrosis, and 50% of essential thrombocythemia.

Diagnosis
Post-Polycythemia Vera Myelofibrosis may be symptomatic or asymptomatic. The symptoms usually develop very slowly. Physical exam findings are non-specific, but may include enlarged liver or spleen, plethora, or gouty nodules. The diagnosis is often suspected on the basis of laboratory tests. Diagnostic procedures involve: Blood tests which may reveal more blood cells than normal, Bone marrow aspiration, specific gene testing.

Treatment
There is no cure for Post-Polycythemia Vera Myelofibrosis. Treatment focuses on reducing the risk of complications. The treatment generally eases the symptoms. The most common treatment for Post-polycythemia Vera Myelofibrosis is having frequent blood withdrawals, using a needle in a vein (phlebotomy). This decreases the number of excess blood cells. Some medications that reduce the number of red blood cells include: Hydroxyruea (Droxia, Hydrea), Interferon alfa-2b (Intron A), Ruxolitinib (Jakafi), Busulfan. Optimizing cardiovascular health such as weight loss, exercise, tobacco cessation, blood pressure control.

Post-Polycythemia Vera Myelofibrosis- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Post-Polycythemia Vera Myelofibrosis pipeline landscape is provided which includes the disease overview and Post-Polycythemia Vera Myelofibrosis treatment guidelines. The assessment part of the report embraces, in depth Post-Polycythemia Vera Myelofibrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Post-Polycythemia Vera Myelofibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Post-Polycythemia Vera Myelofibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Post-Polycythemia Vera Myelofibrosis.

Post-Polycythemia Vera Myelofibrosis Emerging Drugs Chapters

This segment of the Post-Polycythemia Vera Myelofibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Post-Polycythemia Vera Myelofibrosis Emerging Drugs

Navtemadlin: Kartos Therapeutics, Inc.

Navtemadlin (KRT-232) is a potent and selective investigational cancer therapy designed to inhibit the MDM2 protein. In cell cultures and pre-clinical cancer models, navtemadlin (KRT-232) inhibited MDM2 at low drug concentrations and induced dose-dependent activation of p53. Cell-cycle arrest through p21 activation and subsequent induction of cell death by pro-apoptotic Bcl-2 family proteins resulted in complete and durable regression of tumors. Encouraging clinical activity has been reported in patients with advanced cancers, including Myelofibrosis, Acute Myeloid Leukemia, and Merkel cell carcinoma. Currently, the drug is in Phase II/III for Post-Polycythemia Vera MF (Post-PV-MF).

Selinexor: Karyopharm Therapeutics Inc.

Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. This reinitiates and amplifies their tumor suppressor function and is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. It is currently investigated in Phase II clinical trial to evaluate the efficacy and safety in patients with myelofibrosis (PMF, PET-MF, or PPV-MF) refractory or intolerant to JAK1/2 inhibitors.

Post-Polycythemia Vera Myelofibrosis: Therapeutic Assessment

This segment of the report provides insights about the different Post-Polycythemia Vera Myelofibrosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Post-Polycythemia Vera Myelofibrosis

There are approx. 17+ key companies which are developing the therapies for Post-Polycythemia Vera Myelofibrosis. The companies which have their Post-Polycythemia Vera Myelofibrosis drug candidates in the most advanced stage i.e., Phase II/III include, Kartos Therapeutics.

Phases

This report covers around 17+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Post-Polycythemia Vera Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Post-Polycythemia Vera Myelofibrosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Post-Polycythemia Vera Myelofibrosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Post-Polycythemia Vera Myelofibrosis drugs.

Post-Polycythemia Vera Myelofibrosis Report Insights

• Post-Polycythemia Vera Myelofibrosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Post-Polycythemia Vera Myelofibrosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Post-Polycythemia Vera Myelofibrosis drugs?
• How many Post-Polycythemia Vera Myelofibrosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Post-Polycythemia Vera Myelofibrosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Post-Polycythemia Vera Myelofibrosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Post-Polycythemia Vera Myelofibrosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Kartos Therapeutics, Inc.
• Parexel
• Constellation Pharmaceuticals
• Incyte Corporation
• NS Pharma
• Celgene
• Lynk Pharmaceuticals Co., Ltd
• Imago BioSciences, Inc.
• Karyopharm Therapeutics Inc

Key Products

• Navtemadlin
• PXS-5505
• Pelabresib
• Parsaclisib
• NS-018
• Luspatercept
• LNK01002
• IMG-7289
• Selinexor

This product will be delivered within 1-3 business days.